Disclosed are the ERK inhibitors of formula 1.0:
and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS
申请人:Schering Corporation
公开号:EP1966151A1
公开(公告)日:2008-09-10
US8546404B2
申请人:——
公开号:US8546404B2
公开(公告)日:2013-10-01
[EN] POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS<br/>[FR] DERIVES POLYCYCLIQUES D'INDAZOLE INHIBITEURS DES ERK
申请人:SCHERING CORP
公开号:WO2007070398A1
公开(公告)日:2007-06-21
[EN] Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. [FR] La présente invention concerne des inhibiteurs des kinases régulées par des signaux extracellulaires (ERK) de formule 1.0 et leurs sels et solvates pharmaceutiquement acceptables. Q est un cycle pipéridine ou pipérazine qui peut comporter un cycle fusionné ou un pont. Le cycle pipéridine peut comporter une double liaison. Tous les autres substituants sont tels que définis ici. L'invention concerne également des procédés de traitement du cancer à l'aide des composés de formule 1.0.